{'fraction_non_alphanumeric': 0.03383084577114428, 'fraction_numerical': 0.0029850746268656717, 'mean_word_length': 5.937931034482759, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Relationship between peroxisome proliferator activator-receptor (PPAR) and urological cancer].

Recent studies have demonstrated that peroxisome proliferator activator-receptor (PPAR)-gamma ligand induces growth arrest of cancer cells through apoptosis. In this review, we demonstrated the expression of PPAR-gamma in urological cancer (renal cell carcinoma, bladder tumor, prostate cancer, and testicular tumor) tissues as well as the effects of PPAR-gamma ligands. While no marked expression of PPAR-gamma was observed in normal tissue, significant expression was found in all urological cancer tissue. PPAR-gamma ligands (troglitazone and 15dPGJ2) induced the reduction of cell viability with the half-maximal concentration of growth inhibition of renal cell carcinoma, bladder tumor, and prostate cancer cell lines. Cells treated with PPAR-gamma inhibitors showed typical redundant characteristics of apoptosis. PPAR-gamma ligands may mediate potent antiproliferative effects through differentiation.